Related Experiment Video
Updated: May 31, 2026
10:09
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
Dz13: c-Jun downregulation and tumour cell death
1Department of Biomedical and Health Sciences, Faculty of Health, Engineering and Science, Victoria University, St Albans 3021, VIC, Australia.
Chemical Biology & Drug Design
|July 5, 2011
Summary
DNAzymes like Dz13 show promise for cancer treatment by targeting messenger RNA (mRNA). This DNA-based catalyst effectively inhibits tumor growth and induces apoptosis with minimal harm to normal cells.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- DNAzymes are synthetic DNA catalysts that cleave specific mRNA sequences.
- Dz13, a DNAzyme targeting c-Jun mRNA, exhibits anti-tumor and anti-angiogenic properties.
- Off-target effects of Dz13 may contribute to its therapeutic efficacy, but mechanisms in tumor cells are unclear.
Purpose of the Study:
- To investigate the anti-cancer potential of Dz13.
- To explore the mechanisms underlying Dz13's efficacy in various tumor types.
- To evaluate the safety and therapeutic potential of nanoparticle-formulated Dz13.
Main Methods:
- Engineering DNAzymes (Dz13) to cleave specific mRNA (c-Jun mRNA).
- Testing Dz13 efficacy against a panel of tumor cell lines in vitro.
- Formulating Dz13 into biocompatible nanoparticles for in vivo studies.
- Assessing tumor inhibition, apoptosis induction, and safety in normal cells.
Main Results:
- Dz13 demonstrates potent inhibition of multiple tumor types and induces apoptosis.
- Nanoparticle formulation enhances Dz13's therapeutic potential.
- Dz13 shows a favorable safety profile with minimal toxicity to normal cells in vivo.
Conclusions:
- Dz13 is a promising therapeutic agent for various cancers.
- Its ability to induce apoptosis and its safety profile support clinical potential.
- Further research into its mechanisms and formulation could optimize cancer treatment strategies.
Related Concept Videos
01:15Receptor Downregulation in MVBs
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:31The Intrinsic Apoptotic Pathway
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
01:12Loss of Tumor Suppressor Gene Functions
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...